Naomi Osaka has said she does not intend to continue competing if she frequently loses in first round matches after suffering a disappointing 7-5, 6-4 defeat to Australia’s Talia Gibson in her opening match of the Miami Open. Osaka, who received a first-round bye as the 16th seed in Miami, moved sluggishly in an error-strewn performance and was outplayed by the talented 21-year-old Gibson, who wil...
Naomi Osaka has said she does not intend to continue competing if she frequently loses in first round matches after suffering a disappointing 7-5, 6-4 defeat to Australia’s Talia Gibson in her opening match of the Miami Open. Osaka, who received a first-round bye as the 16th seed in Miami, moved sluggishly in an error-strewn performance and was outplayed by the talented 21-year-old Gibson, who will play Iva Jovic in the next round. A question on Osaka’s plans for the upcoming clay court season prompted the 28-year-old to reflect on the difficulties of juggling motherhood with her goals as a professional tennis player. Osaka, who said she would play an abbreviated clay season starting at the Madrid Open, does not believe she can be the best mother possible while pursuing those goals. “I feel like this also is a dilemma for me,” Osaka told a small group of reporters. “Obviously, I would love to play, but like I said last year … for me, my daughter is very important, and I want to be a mom. I want to be the best mom I can, but sometimes I feel like I know what I have to do to become a really good player, and it’s very difficult. I’m not going to play Charleston. I hope I can play Madrid, Rome and then obviously the French Open. Things have been challenging for Osaka since returning to competition in 2024 soon after giving birth to her daughter, Shai. She seemed to take a significant step forward at the end of last year, reaching the US Open semi-finals and the final of the Canada Open in Montreal. Osaka’s progress has also been hampered by injuries. She was forced to withdraw from the Australian Open after a relapse of her chronic abdominal injury, which she says is connected to her pregnancy. Osaka said she has been struggling with a back injury over the past week, which she joked was due to old age. “Your girl’s getting old out here,” she said, laughing. “For me, like I said last year, I’m not going to stay on tour if I’m losing in the first round,” Osaka added. “I’d...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Palantir Technologies (NasdaqGS:PLTR) has had its Maven AI technology designated as a "program of record" by the U.S. Department of Defense. The designation formalizes Maven AI’s adoption across all U.S. military branches and secures stable, long term funding. This move positions...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Palantir Technologies (NasdaqGS:PLTR) has had its Maven AI technology designated as a "program of record" by the U.S. Department of Defense. The designation formalizes Maven AI’s adoption across all U.S. military branches and secures stable, long term funding. This move positions Maven AI as a core component in U.S. military operations, replacing ad hoc or pilot style contracts. Palantir, known for its data analytics and AI software for government and commercial clients, now has Maven AI embedded more formally within U.S. defense planning and budgeting. For readers tracking defense related software providers, this designation stands out because it ties Palantir’s technology directly into the U.S. military’s standard programs rather than short term projects. For investors watching NasdaqGS:PLTR, the new status for Maven AI may influence how they think about the durability of Palantir’s government revenue and the depth of its relationship with the Department of Defense. It also gives context for comparing Palantir’s role against other defense and AI software suppliers that may still be working largely on pilots or one off contracts. Stay updated on the most important news stories for Palantir Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Palantir Technologies. NasdaqGS:PLTR Earnings & Revenue Growth as at Mar 2026 📰 Beyond the headline: 0 risks and 2 things going right for Palantir Technologies that every investor should see. Quick Assessment ⚖️ Price vs Analyst Target : At US$150.68 versus a US$186.60 consensus target, the price is roughly 19% below where analysts, on average, expect it to be. ❌ Simply Wall St Valuation : Shares are trading about 23.5% above Simply Wall St's estimated fair value, which flags valuation as stretched. ✅ Recent Momentum: A 30 day return of ...
李強：十五五規劃綱要為中國新藍圖、世界新機遇 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】為期兩天的中國發展高層論壇在北京開幕，總理李強稱「十五五」規劃綱要是中國發展的新藍圖及世界發展的新機遇。 李強：「中國的...
李強：十五五規劃綱要為中國新藍圖、世界新機遇 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】為期兩天的中國發展高層論壇在北京開幕，總理李強稱「十五五」規劃綱要是中國發展的新藍圖及世界發展的新機遇。 李強：「中國的進出口是在規則框架下進行的公平貿易，當然我們也高度關注貿易夥伴的關切，願意同各方一起推動貿易優化平衡發展。『十五五』規劃綱要，這不僅是中國發展的新藍圖，也是世界發展的新機遇。」 李強又稱保護主義不是解決問題的靈丹妙藥，應擴大自由貿易，反對無序、非理性的惡性競爭。中方將繼續維護公平競爭的市場秩序，促進全球產供鏈穩定安全，打造良好營商環境，全面落實外資企業國民待遇，讓來華企業安心發展。
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Palantir Technologies (NasdaqGS:PLTR) has had its Maven AI technology designated as a "program of record" by the U.S. Department of Defense. The designation formalizes Maven AI’s adoption across all U.S. military branches and secures stable, long term funding. This move positions...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Palantir Technologies (NasdaqGS:PLTR) has had its Maven AI technology designated as a "program of record" by the U.S. Department of Defense. The designation formalizes Maven AI’s adoption across all U.S. military branches and secures stable, long term funding. This move positions Maven AI as a core component in U.S. military operations, replacing ad hoc or pilot style contracts. Palantir, known for its data analytics and AI software for government and commercial clients, now has Maven AI embedded more formally within U.S. defense planning and budgeting. For readers tracking defense related software providers, this designation stands out because it ties Palantir’s technology directly into the U.S. military’s standard programs rather than short term projects. For investors watching NasdaqGS:PLTR, the new status for Maven AI may influence how they think about the durability of Palantir’s government revenue and the depth of its relationship with the Department of Defense. It also gives context for comparing Palantir’s role against other defense and AI software suppliers that may still be working largely on pilots or one off contracts. Stay updated on the most important news stories for Palantir Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Palantir Technologies. NasdaqGS:PLTR Earnings & Revenue Growth as at Mar 2026 📰 Beyond the headline: 0 risks and 2 things going right for Palantir Technologies that every investor should see. Quick Assessment ⚖️ Price vs Analyst Target : At US$150.68 versus a US$186.60 consensus target, the price is roughly 19% below where analysts, on average, expect it to be. ❌ Simply Wall St Valuation : Shares are trading about 23.5% above Simply Wall St's estimated fair value, which flags valuation as stretched. ✅ Recent Momentum: A 30 day return of ...
Key Points Kate Mitchell acquired 2,350 RAL shares on Feb. 10, 2026, for a transaction value of ~$100,000 at around $42.48 per share. All shares are held indirectly through The Wesley and Katherine Mitchell Living Trust, with no direct holdings reported after the transaction. After the transaction, Mitchell held 8,411 shares indirectly and 0 shares directly. 10 stocks we like better than Ralliant ...
Key Points Kate Mitchell acquired 2,350 RAL shares on Feb. 10, 2026, for a transaction value of ~$100,000 at around $42.48 per share. All shares are held indirectly through The Wesley and Katherine Mitchell Living Trust, with no direct holdings reported after the transaction. After the transaction, Mitchell held 8,411 shares indirectly and 0 shares directly. 10 stocks we like better than Ralliant › Kate Mitchell, Director of Ralliant (NYSE:RAL), reported an open-market purchase of 2,350 shares for a total consideration of ~$100,000, according to a SEC Form 4 filing dated Feb. 12, 2026. Transaction summary Metric Value Shares traded 2,350 Transaction value $99,828.00 Post-transaction shares (direct) 0 Post-transaction shares (indirect) 8,411 Transaction value based on SEC Form 4 reported price ($42.48). Key questions What was the structure and entity context of this transaction? All 2,350 shares were purchased indirectly through The Wesley and Katherine Mitchell Living Trust, where Mitchell serves as trustee and beneficiary, with no shares acquired or held directly. All 2,350 shares were purchased indirectly through The Wesley and Katherine Mitchell Living Trust, where Mitchell serves as trustee and beneficiary, with no shares acquired or held directly. How did this purchase impact Mitchell's overall ownership stake? The acquisition raised the trust's position by 38.77%, increasing indirect holdings from 6,061 to 8,411 shares, while direct ownership remains at zero. Company overview Metric Value Revenue (TTM) $2.07 billion Net Loss (TTM) $1.22 billion Dividend yield 0.20% Price (as of market close 3/21/26) $40.80 Company snapshot Ralliant provides advanced measurement and sensor technologies for defense and space applications. It designs and manufactures precision instruments, test and measurement systems, and specialty sensors. The company's strategy centers on innovation in precision measurement and sensor technology. What this transaction means for investors Ralli...
Key Points DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $2.36 million, reflecting both trading activity and price movements. After the trade, the fund held 476,826 shares valued at $15.61 million 10 stocks we like better than Axo...
Key Points DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $2.36 million, reflecting both trading activity and price movements. After the trade, the fund held 476,826 shares valued at $15.61 million 10 stocks we like better than Axogen › DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February 17, 2026, SEC filing. What happened According to a SEC filing dated February 17, 2026, DAFNA Capital Management reduced its position in Axogen (NASDAQ:AXGN) by 265,456 shares during the fourth quarter of 2025. The estimated transaction value of the sale is $6.53 million, calculated using the average closing price for the quarter. The fund finished the period with 476,826 shares of Axogen, worth $15.61 million at quarter end. What else to know After the sale, Axogen represents 3.63% of the fund's 13F reportable assets under management. Top holdings after the filing include: NASDAQ:RVMD: $48.15 million (11.33% of AUM) NYSEMKT:XBI: $41.03 million (9.65% of AUM) NYSEMKT:STXS: $31.47 million (7.40% of AUM) NASDAQ:ATRC: $23.63 million (5.56% of AUM) NASDAQ:CYTK: $23.57 million (5.55% of AUM) As of Friday, AXGN shares were priced at $30.78, up 71% over the past year and well outperforming the S&P 500, which is instead up about 15% in the same period. Company overview Metric Value Market Capitalization $1.6 billion Revenue (TTM) $225.2 million Net Income (TTM) ($15.7 million) Price (as of Friday) $30.78 Company Snapshot AxoGen develops and markets surgical solutions for peripheral nerve repair, including Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, Avive Soft Tissue Membrane, and AxoTouch two-point discriminator. The firm generates re...
Key Points On March 25, 2026, The Vita Coco Company will join the S&P SmallCap 600, effective prior to the opening of the trading day. The company's stock has been performing strong in previous months, and it recently released a new flavor for one if its popular products. 10 stocks we like better than Vita Coco › Corey Baker, Chief Financial Officer of The Vita Coco Company, Inc. (NASDAQ:COCO), di...
Key Points On March 25, 2026, The Vita Coco Company will join the S&P SmallCap 600, effective prior to the opening of the trading day. The company's stock has been performing strong in previous months, and it recently released a new flavor for one if its popular products. 10 stocks we like better than Vita Coco › Corey Baker, Chief Financial Officer of The Vita Coco Company, Inc. (NASDAQ:COCO), disclosed the sale of 4,000 shares of common stock on March 17, 2026 and March 18, 2026, as detailed in the SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 4,000 Transaction value ~$236,000 Post-transaction shares (direct) 27,951 Post-transaction value (direct ownership) ~$1.56 million Transaction value based on SEC Form 4 weighted average purchase price ($58.98); post-transaction value based on March 18, 2026 market close ($52.88). Key questions What proportion of Baker's holding was impacted by this trade? The sale accounted for 12.52% of Baker's direct common stock holdings prior to the transaction. The sale accounted for 12.52% of Baker's direct common stock holdings prior to the transaction. What is the context of Baker’s transactions? The transactions were executed under a Rule 10b5-1 trading plan, allowing Baker to sell the shares in advance. Company overview Metric Value Revenue (TTM) $609.78 million Net income (TTM) $71.32 million Employees 319 1-year price change 50.44% * 1-year price change calculated as of March 21, 2026. Company snapshot The Vita Coco Company, Inc. develops and distributes coconut-based and functional hydration products, including coconut water, coconut oil, coconut milk, hydration drink mixes, sparkling water, plant-based energy drinks, purified water, and protein-infused fitness drinks. It targets health-conscious consumers in the United States, Canada, Europe, the Middle East, and the Asia Pacific, selling primarily through large retailers, convenience stores, and online platforms. What this transaction means for inves...
"If you are not happy about this government, then in 2027 [you can] just kick it off the bus, change to another government. Now, the matter of the referendum is what counts."
"If you are not happy about this government, then in 2027 [you can] just kick it off the bus, change to another government. Now, the matter of the referendum is what counts."
Key Points DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quarter-end value of the position rose by $7.25 million, reflecting both the share increase and stock price changes during the period. Post-trade, the fund held 955,235 shares valued at $10.78 ...
Key Points DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quarter-end value of the position rose by $7.25 million, reflecting both the share increase and stock price changes during the period. Post-trade, the fund held 955,235 shares valued at $10.78 million, accounting for 2.51% of AUM, which places it outside the fund's top five holdings. 10 stocks we like better than Biohaven › DAFNA Capital Management reported a buy of 720,000 shares of Biohaven (NYSE:BHVN) in a February 17, 2026, SEC filing, with the estimated transaction value at $8.92 million based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, DAFNA Capital Management increased its position in Biohaven by 720,000 shares during the fourth quarter of 2025. The estimated value of this trade was $8.92 million, based on quarterly average pricing. The stake’s total value at quarter-end was $10.78 million, up $7.25 million from the previous period, a change reflecting both the additional shares and movements in the stock’s price. What else to know DAFNA’s Biohaven position now represents 2.51% of its reportable U.S. equity assets after this buy. Top five holdings after the filing: NASDAQ:RVMD: $48.15 million (11.3% of AUM) NYSEMKT:XBI: $41.03 million (9.7% of AUM) NYSEMKT:STXS: $31.47 million (7.4% of AUM) NASDAQ:ATRC: $23.63 million (5.6% of AUM) NASDAQ:CYTK: $23.57 million (5.5% of AUM) As of Friday, Biohaven shares were priced at $8.93, down a staggering 68% over the past year and significantly underperforming the S&P 500, which is instead up about 15% in the same period. Company overview Metric Value Price (as of Friday) $8.93 Market Capitalization $1.3 billion Net Income (TTM) ($738.8 million) Company snapshot Biohaven develops clinical-stage therapies targeting neurological and immunoscience diseases, with no commerciali...
编程模型竞争加剧，模型厂商开发应用挤压应用公司 Cursor于3月19日发布新一代编程模型Composer-2，据称能以较低价格实现介于OpenAI GPT5.4（high）和Anthropic Claude Opus 4.6（high）的性能。图：IC photo 【财新网】 Cursor将模型研发确立为首要目标后，其新模型陷入侵权争议。针对新模型Composer-2是否由月之暗面Kimi K2...
编程模型竞争加剧，模型厂商开发应用挤压应用公司 Cursor于3月19日发布新一代编程模型Composer-2，据称能以较低价格实现介于OpenAI GPT5.4（high）和Anthropic Claude Opus 4.6（high）的性能。图：IC photo 【财新网】 Cursor将模型研发确立为首要目标后，其新模型陷入侵权争议。针对新模型Composer-2是否由月之暗面Kimi K2.5模型微调而来的广泛质疑，美国AI编程应用Cursor联合创始人、COO阿曼·桑格（Aman Sanger ）于3月21日做出确认回应。 Cursor于3月19日发布新一代编程模型Composer-2，据称能以较低价格实现介于OpenAI GPT5.4（high）和Anthropic Claude Opus 4.6（high）的性能。但开发者在使用时发现，其代码中的模型ID为“Kimi-k2p5”，由此提出Composer-2就是带强化学习的K2.5。
President Donald Trump threatened to attack Iran’s power plants if the country didn’t swiftly open the Strait of Hormuz to commercial ship traffic that has paralyzed the passage of oil and gas cargoes. Trump said in a social media post on Saturday that he would “hit and obliterate” Iran’s power plants, beginning with the biggest one, if it didn’t open the strait within 48 hours. The comments from ...
President Donald Trump threatened to attack Iran’s power plants if the country didn’t swiftly open the Strait of Hormuz to commercial ship traffic that has paralyzed the passage of oil and gas cargoes. Trump said in a social media post on Saturday that he would “hit and obliterate” Iran’s power plants, beginning with the biggest one, if it didn’t open the strait within 48 hours. The comments from Trump, on his Truth Social media platform, marked a dramatic escalation in the US president’s rhetoric about the strait, just 24 hours after he said the responsibility for policing it would fall to the countries reliant on shipping through the corridor. Threats have nearly paralyzed the shipment of commodities through the Strait of Hormuz, which provides transit for roughly 20% of the world’s oil and gas. The resulting energy supply shock has sent crude prices soaring, with international benchmark Brent futures closing at $112.19 on Friday. The remarks mark a shift in tone since Trump on Friday said the US was considering “winding down” military efforts in the Persian Gulf. Trump previously had been pressuring allies to deploy forces to help the US secure the strait.